Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
Transplantation and Cellular Therapy|December 19, 2024
Incidence, Risk Factors, and Outcomes of BK Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplantation From HLA-Matched and Haploidentical Donors With Post-Transplant CyclophosphamidePedro Chorão, Marta Villalba, Aitana Balaguer-Roselló, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 15, 2025
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation TrialsDavid F Moreno, Albert Oriol, Javier de la Rubia, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|March 17, 2021
Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?Manuel Guerreiro, Cristóbal Aguilar-Gallardo, Juan Montoro, et al.
Blood|April 24, 2019
Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only diseaseJuan-José Lahuerta, Ana Jiménez-Ubieto, Bruno Paiva, et al.
Leukemia & Lymphoma|March 23, 2002
Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myelomaJuan José Lahuerta, Carlos Grande, Joan Blade, et al.
Blood|December 16, 2015
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysisBruno Paiva, María Victoria Mateos, Luis Ignacio Sanchez-Abarca, et al.
Cancers|June 10, 2023
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome MappingÁlvaro Díaz-González, Elvira Mora, Gayane Avetisyan, et al.
Blood|July 14, 2012
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyLaura Rosiñol, Albert Oriol, Ana Isabel Teruel, et al.
Blood|April 13, 2011
Long-term prognostic significance of response in multiple myeloma after stem cell transplantationJoaquin Martinez-Lopez, Joan Blade, María-Victoria Mateos, et al.
Blood|September 18, 2024
Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myelomaNoemí Puig, Cristina Agulló, Teresa Contreras, et al.
Pageof 20